The American College of Physicians issued new guidelines for Type 2 diabetes treatment, which for the first time recommends the use of GLP-1s and another class of diabetes drugs called SGLT-2s alongside metformin, though this may exacerbate the ongoing drug shortages of several GLP-1s.
In the updated guidelines, the ACP also recommends against the use of DPP-4 inhibitors alongside metformin, because new evidence showed DPP-4s didn’t reduce disease or death.—may be a “significant barrier” in providing patients with access to treatment, according to an accompanying editorial by Fatima Zyed, an internal medicine doctor at Duke University’s Division of General Internal Medicine.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: